Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

AiCuris Anti-infective Cures' pritelivir achieves primary endpoint in phase I trial

Aug. 24, 2016

Pfizer to acquire AstraZeneca's small molecule anti-infectives business

Aug. 24, 2016

EMA validates Cempra's MAA for solithromycin

Aug. 24, 2016

Biotron identifies new compounds in Zika program, signs agreement with NIAID

Aug. 24, 2016

AstraZeneca discloses potent capsid-binding human rhinovirus inhibitor AZN-001

Aug. 23, 2016

New phase II trial explores safety and immunogenicity of TSI-GSD-210 for Western equine encephalitis

Aug. 22, 2016

Shionogi initiates phase III trial of S-649266 to treat carbapenem-resistant Gram-negative bacteria

Aug. 22, 2016

PATH initiates phase I trial of MCV-5 meningococcal conjugate vaccine

Aug. 22, 2016

Chinese clinical trial authorization for TaiGen's furaprevir

Aug. 19, 2016

NIAID funding supports testing of Kineta's broad-spectrum antivirals in preclinical Zika models

Aug. 19, 2016

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...